全文获取类型
收费全文 | 2414篇 |
免费 | 112篇 |
国内免费 | 313篇 |
出版年
2024年 | 5篇 |
2023年 | 59篇 |
2022年 | 106篇 |
2021年 | 81篇 |
2020年 | 68篇 |
2019年 | 100篇 |
2018年 | 62篇 |
2017年 | 61篇 |
2016年 | 55篇 |
2015年 | 90篇 |
2014年 | 115篇 |
2013年 | 142篇 |
2012年 | 89篇 |
2011年 | 141篇 |
2010年 | 106篇 |
2009年 | 151篇 |
2008年 | 138篇 |
2007年 | 136篇 |
2006年 | 167篇 |
2005年 | 139篇 |
2004年 | 117篇 |
2003年 | 104篇 |
2002年 | 86篇 |
2001年 | 75篇 |
2000年 | 68篇 |
1999年 | 64篇 |
1998年 | 46篇 |
1997年 | 54篇 |
1996年 | 35篇 |
1995年 | 23篇 |
1994年 | 30篇 |
1993年 | 25篇 |
1992年 | 23篇 |
1991年 | 23篇 |
1990年 | 9篇 |
1989年 | 11篇 |
1988年 | 4篇 |
1987年 | 6篇 |
1986年 | 5篇 |
1985年 | 8篇 |
1984年 | 4篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1979年 | 1篇 |
1978年 | 2篇 |
1974年 | 1篇 |
1972年 | 1篇 |
排序方式: 共有2839条查询结果,搜索用时 15 毫秒
11.
本文对吸附精制百白破混合制剂的不同配方进行了实验,结果表明,新一代吸附精制百白破混合制剂最佳配方为:精制百日咳菌苗18μgPN/ml、精制白喉类毒素为30Lf/ml、精制破伤风类毒素为10Lf/ml。由该配方组成的吸附精制百白破混合制剂,其中百日咳菌苗的毒性试验BWDU/ml、LPU/ml、HSU/ml三种指标均符合制检规程要求。其效力单位(IU/ml)超过规程要求一倍以上,精制白喉和破伤风类毒素的安全试验均符合规程要求,白类效力试验≥80-100%,破类效力试验≥0.5-4.5IU/ml。上述结果说明本文提出的配方作为新一代精制百白破混合制剂的配方是适宜和实用的。 相似文献
12.
《Revista espa?ola de geriatría y gerontología》2023,58(3):125-133
IntroductionBNT162b2 (BioNTech and Pfizer) is a nucleoside-modified mRNA vaccine that provides protection against SARS-CoV-2 infection and is generally well tolerated. However, data about its efficacy, immunogenicity and safety in people of old age or with underlying chronic conditions are scarce.PurposeTo describe BNT162b2 (BioNTech and Pfizer) COVID-19 vaccine immunogenicity, effectiveness and reactogenicity after complete vaccination (two doses), and immunogenicity and reactogenicity after one booster, in elders residing in nursing homes (NH) and healthy NH workers in real-life conditions.MethodsObservational, ambispective, multicenter study. Older adults and health workers were recruited from three nursing homes of a private hospital corporation located in three Spanish cities. The primary vaccination was carried out between January and March 2021. The follow-up was 13 months. Humoral immunity, adverse events, SARS-CoV-2 infections, hospitalizations and deaths were evaluated. Cellular immunity was assessed in a participant subset.ResultsA total of 181 residents (mean age 84.1 years; 89.9% females, Charlson index ≥2: 45%) and 148 members of staff (mean age 45.2 years; 70.2% females) were surveyed (n:329). After primary vaccination of 327 participants, vaccine response in both groups was similar; ≈70% of participants, regardless of the group, had an antibody titer above the cut-off considered currently protective (260 BAU/ml). This proportion increased significantly to ≈ 98% after the booster (p < 0.0001 in both groups). Immunogenicity was largely determined by a prior history of COVID-19 infection. Twenty residents and 3 workers were tested for cellular immunity. There was evidence of cellular immunity after primary vaccination and after booster. During the study, one resident was hospitalized for SARS-CoV-2. No SARS-CoV-2-related deaths were reported and most adverse events were mild.ConclusionsOur results suggest that the BNT162b2 mRNA COVID-19 vaccine is immunogenic, effective and safe in elderly NH residents with underlying chronic conditions. 相似文献
13.
S. Chatfield M. Roberts P. Londono I. Cropley G. Douce G. Dougan 《FEMS immunology and medical microbiology》1993,7(1):1-7
Abstract Safe, live attenuated Salmonella strains can be produced by introducing defined non-reverting mutations into the chromosome. Such rationally attenuated strains have proved to be excellent oral vaccines in several animal species and can therefore be considered as candidate vaccines against invasive salmonellosis in both animals and man. A panel of attenuating lesions is now available from which it is possible to tailor the level of attenuation and hence produce strains with different immunogenic properties. Because of the spectrum of immune responses produced by such Salmonella vaccine strains they have been utilised extensively as vectors for delivering heterologous antigens to the mammalian immune system. We have focussed on the development of a single dose oral tetanus vaccine based on attenuated Salmonella strains expressing a non-toxic, immunogenic protein derived from tetanus toxin (fragment C). Several different expression systems have been used for fragment C and candidate vaccine strains have been constructed that are capable of protecting orally immunised mice against a lethal challenge with tetanus toxin. An oral tetanus vaccine may help to reduce the mortality rate from tetanus in the developing world by overcoming the problems associated with the implementation of vaccine programmes using the current parenteral vaccine. 相似文献
14.
15.
DNA immunization: Effects of vehicle and route of administration on the induction of protective antiviral immunity 总被引:2,自引:0,他引:2
Masayuki Yokoyama Jie Zhang J.Lindsay Whitton 《FEMS immunology and medical microbiology》1996,14(4):221-230
Abstract The effectiveness of DNA immunization has been demonstrated in several model systems, usually following intramuscular injection of DNA in saline, or topical administration to the skin. In this study we have compared DNA delivered by three routes (intramuscular, intravenous, and intraperitoneal) and, for each route, in two vehicles (cationic liposome complex and pH sensitive liposome). These two lipid vehicles were evaluated because they are frequently used in gene therapy studies, but their immunogenicity has not been extensively studied. Each of these six combinations has been evaluated not only by assay of marker gene expression in a variety of tissues, but also by measurement of biologically-relevant parameters of immunity induction of antibodies, cytotoxic T lymphocytes, and protection against viral challenge. By both criteria (marker gene expression and induced immunity), the outcomes vary markedly among the six combinations. The combination leading to maximal marker gene expression (DNA with cationic lipid, administered i.v.) also induces detectable antibodies and CTL, and is the only one of the six combinations to induce immune responses comparable to those seen following i.m. injection of DNA in saline. However, marker gene expression can be detected in other combinations in the absence of induced immunity thus the value of marker gene expression in predicting the protection induced by a microbial antigen is questionable suggesting that, when evaluating various promoter constructs, marker gene expression may not adequately replace the direct measurement of biological outcomes. 相似文献
16.
Crystal structure of a non-toxic mutant of heat-labile enterotoxin, which is a potent mucosal adjuvant. 总被引:1,自引:0,他引:1
下载免费PDF全文
![点击此处可从《Protein science : a publication of the Protein Society》网站下载免费的PDF全文](/ch/ext_images/free.gif)
F. van den Akker M. Pizza R. Rappuoli W. G. Hol 《Protein science : a publication of the Protein Society》1997,6(12):2650-2654
Two closely related bacterial toxins, heat-labile enterotoxin (LT-I) and cholera toxin (CT), not only invoke a toxic activity that affects many victims worldwide but also contain a beneficial mucosal adjuvant activity that significantly enhances the potency of vaccines in general. For the purpose of vaccine design it is most interesting that the undesirable toxic activity of these toxins can be eliminated by the single-site mutation Ser63Lys in the A subunit while the mucosal adjuvant activity is still present. The crystal structure of the Ser63Lys mutant of LT-I is determined at 2.0 A resolution. Its structure appears to be essentially the same as the wild-type LT-I structure. The substitution Ser63Lys was designed, based on the wild-type LT-I crystal structure, to decrease toxicity by interfering with NAD binding and/or catalysis. In the mutant crystal structure, the newly introduced lysine side chain is indeed positioned such that it could potentially obstruct the productive binding mode of the substrate NAD while at the same time its positive charge could possibly interfere with the critical function of nearby charged groups in the active site of LT-I. The fact that the Ser63Lys mutant of LT-I does not disrupt the wild-type LT-I structure makes the non-toxic mutant potentially suitable, from a structural point of view, to be used as a vaccine to prevent enterotoxigenic E. coli infections. The structural similarity of mutant and wild-type toxin might also be the reason why the inactive Ser63Lys variant retains its adjuvant activity. 相似文献
17.
综述了近年来有关利用基因转移技术修饰肿瘤细胞制备肿瘤基因工程疫苗的最新研究进展,着重阐述了逆转录病毒载体介导的基因转移及其安全性;归纳了目前可用于肿瘤基因工程疫苗的各种目的基因的特点及作用并对这类肿瘤疫苗制备过程中所存在的问题进行了分析. 相似文献
18.
新生儿乙型肝炎血源疫苗的免疫策略和成本效益分析 总被引:5,自引:0,他引:5
比较了6种新生儿血源乙型肝炎疫苗的免疫方案,其中一种只免疫HBsAg阳性母亲的婴儿效果最差,群体有效率仅17.79%,成本效益比值亦低。其它5种方案都是对全部新生儿进行免疫,效果均好。这5种方案是10μg与3μg两种剂量的不同组合,其中用10μgg3JI疫者成本效益比值最高,有效率为78.61%。HBsAg阳性母亲新生儿按30μg×3,而阴性母亲婴儿首剂用30μg,第2、3剂各10μg,有效率高达87.47%,但成本效益比值最低。应根据我国经济发展的水平与群众的承受能力,对各地区选用不同的新生儿免疫方案。 相似文献
19.
HBsAg阴性母亲的新生儿接种不同剂量乙型肝炎血源疫苗的效果 总被引:2,自引:0,他引:2
HBsAg阴位母亲的新生儿,按0,1、6月程序分别接种10-10-10μg(1组)、20-10-10μg(2组)和30-10-10μg(3组)乙型肝炎血源疫苗。第一针后一年,检查抗-HBs阳转率,分别为87.60%,90.64%和88.97%,无统计学显著差异。3针10μg组免疫后l~4年抗-HBs阳性率分别为88.31%、81.08%、80.10%和78.39%,虽稍下降,但无统计学显著差异。3个剂量组HBsAg阳性率分别为0.71%,0.49%和0.74%,说明HBsAg阴性母亲的新生儿,用国产血源HBsAg疫苗免疫以10μ×3效果较理想。 相似文献
20.
N. C. Smith 《International journal for parasitology》1992,22(8):1047-1082